Calreticulin mutant mice develop essential thrombocythemia that is ameliorated by the JAK inhibitor ruxolitinib

Mutations of calreticulin (CALR) are detected in 25–30% of patients with essential thrombocythemia (ET) or primary myelofibrosis and cause frameshifts that result in proteins with a novel C-terminal. We demonstrate that CALR mutations activated signal transducer and activator of transcription 5 (STA...

Descripción completa

Detalles Bibliográficos
Autores principales: Shide, K, Kameda, T, Yamaji, T, Sekine, M, Inada, N, Kamiunten, A, Akizuki, K, Nakamura, K, Hidaka, T, Kubuki, Y, Shimoda, H, Kitanaka, A, Honda, A, Sawaguchi, A, Abe, H, Miike, T, Iwakiri, H, Tahara, Y, Sueta, M, Hasuike, S, Yamamoto, S, Nagata, K, Shimoda, K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5420793/
https://www.ncbi.nlm.nih.gov/pubmed/27807369
http://dx.doi.org/10.1038/leu.2016.308

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5420793/
https://www.ncbi.nlm.nih.gov/pubmed/27807369
http://dx.doi.org/10.1038/leu.2016.308

Ejemplares similares